Studieoverzicht

 
 
  2019-01 TIBET       Feasibility       Advanced/metastatic       HER2- HR+       Both pre- and postmenopausal  
  2017-04 BYLieve       Open       Advanced/metastatic       HER2- HR+       Not applicable  
  2017-03 SONIA       Open       Advanced/metastatic       HER2- HR+       Not applicable  
  2015-02 MonaLEEsa-3       Follow up       Advanced/metastatic       HER2- HR+       Postmenopausal  
  2015-01 Monarch-3       Follow up       Advanced/metastatic       HER2- HR+       Postmenopausal  
  2014-02 BRAVO       Follow up       Advanced/metastatic       HER2-, any HR       Both pre- and postmenopausal  
  2014-01 MONALEESA-2       Follow up       Advanced/metastatic       HER2- HR+       Postmenopausal  
  2013-06 Biomarker Study Everolimus       Follow up       Advanced/metastatic       HER2- HR+       Postmenopausal  
  2013-05 BELLE-3       Follow up       Advanced/metastatic       HER2- HR+       Postmenopausal  
  2013-03 PERNETTA       Follow up       Advanced/metastatic       HER2+, any HR       Both pre- and postmenopausal  
  2013-01 Triple-B       Open       Advanced/metastatic       TNBC       Both pre- and postmenopausal  
  2012-01 BALLET       Closed       Advanced/metastatic       HER2- HR+       Postmenopausal  
  2011-01 Abiraterone       Follow up       Advanced/metastatic       HER2- HR+       Postmenopausal  
  2010-05 SUBMIT       Closed       Advanced/metastatic       Any HER2, any HR       Both pre- and postmenopausal  
  2010-02 STOP&GO       Follow up       Advanced/metastatic       HER2-, any HR       Both pre- and postmenopausal  
  2009-05 BOLERO 2       Closed       Advanced/metastatic       HER2- HR+       Postmenopausal  
  2008-03 HAT       Closed       Advanced/metastatic       HER2+, any HR       Both pre- and postmenopausal  
  2008-02 A6181099       Closed       Advanced/metastatic       Any HER2, any HR       Both pre- and postmenopausal  
  2006-06 ATX       Closed       Advanced/metastatic       HER2-, any HR       Both pre- and postmenopausal  
  2006-02 OMEGA       Closed       Advanced/metastatic       Any HER2, any HR       Postmenopausal  
  2004-02 TBP       Closed       Advanced/metastatic       HER2+, any HR       Both pre- and postmenopausal  
  2002-02 Hertax       Closed       Advanced/metastatic       HER2+, any HR       Both pre- and postmenopausal